NCT06375343View on ClinicalTrials.gov

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 30, 2026

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions
Dry Eye DiseaseDry Eye SensationOcular Surface Disease
Interventions
DRUG

PRO-240

-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.

DRUG

Optive®

\- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY